Hoping for a little tail wind share price boost from the SNG RNS today.
IFN-beta is a naturally-occurring protein which orchestrates the body's antiviral responses. It is a well-tolerated drug and there is growing evidence that deficiency in IFN-beta production in the lungs could put vulnerable patient groups at risk of developing severe lower respiratory tract disease during respiratory viral infections. GLA
Like so many I am sat quietly waiting the update we all hope for. Every so often I have a little peep for an RNS and glance at the trades, it did make me chuckle to see so so many 1 trades firing in yesterday. For those who believe !!! ; ) LOL. Gla
Yourgene featuring on Government site - ExpressTest by Cignpost Diagnostics using YourGene Health UK Ltd for Self swab at home and supervised testing. https://www.find-travel-test-provider.service.gov.uk/maintenance#list-of-test-providers
Positive news.
SUPP are gradually moving up and back towards the NAV. The spread is reducing nicely and whoever is drip selling their holding the shares appear to hoovered up quietly. Possible anticipation to gain traction and value from the Oxford Nanopore IPO ? Keep it up Schroders. Spkr.
Beardozer, I fully agree with you opinion, SUPP is undervalued but for obvious reasons over the last 2 years market sentiment has been against us. I have had no options but to average down but feel very confident in my decision to buy. I am not so sure the goldmine is short term, steady burn and market re-valuation is what we need. I sincerely believe Schroders will not allow SUPP to fail. Nice one BD
Acquisition of Greenlight
Proposed Placing of Ordinary Shares
and
Notice of General Meeting
Brave Bison Group plc (AIM: BBSN), the social media and marketing group, is pleased to announce that it has entered into a conditional agreement to acquire the entire issued share capital of Greenlight Digital Limited and Greenlight Commerce Limited (together, "Greenlight") for an aggregate consideration of c.£6.8 million (the "Acquisition").
Greenlight is a digital advertising and technology company with more than 120 employees in the UK and across Eastern Europe. Greenlight works with blue-chip brands and omni-channel retailers on digital advertising and eCommerce technology systems. Current Greenlight clients include Dixons Carphone, Muller, GAP, Furniture Village and New Balance.
Brave Bison also announces that, in order to finance the Acquisition, the Company has conditionally raised gross proceeds of c.£6.2 million by way of a placing of 455,555,560 new ordinary shares of 0.1 penny each in the Company ("Ordinary Shares") at a price of 1.35 pence per Ordinary Share (the "Placing Price") with new and existing institutional and other investors (the "Placing"). The Placing is conditional on, inter alia, shareholder approval of certain resolutions to be proposed at a general meeting of the Company.
The Vendors of Greenlight will receive a total net consideration comprising an aggregate of £6.75 million in cash and 6,601,000 new Ordinary Shares at the Placing Price (the "Consideration Shares").
Transaction Highlights:
· Transformational acquisition that is expected to be significantly earnings accretive in the current year and beyond. In FY20, Greenlight generated revenue of c.£14.3 million and Adjusted EBITDA of c.£0.8 million, more than doubling the Group's revenues on a pro-forma basis.
· Strategic leap for Brave Bison through the acquisition of in-demand and high-growth digital-first capabilities, such as Paid & Organic Media and eCommerce Technology. The combination with Greenlight brings new talent, new services and new opportunities to the Group, including further expansion into APAC using Brave Bison's existing operations in Singapore as a beachhead.
Nuformix plc
6th Floor
60 Gracechurch Street London EC3V 0HR
22 July 2021
Dear Shareholder,
I am writing to you as the Non-Executive Chairman of Nuformix plc. This letter comes as a response to a number of enquires we have had regarding the RNS we issued on Wednesday morning, 21 July stating that Dr Anne Brindley has decided to step down from her role as CEO of the Company. I understand the frustration and confusion from our valued shareholders on this news, feelings shared by the Board, so I wanted to address some of the concerns in this letter. Her announcement came after I had written my Chairman’s statement in the upcoming Annual Report.
Anne’s resignation was unexpected and is the result of a significant job offer she could not refuse from previous colleagues – it is no reflection on Nuformix or her view of the opportunities in the Nuformix pipeline.
Anne understands the difficulties this causes the Company and has committed to working diligently on the ongoing Company projects during her six month notice period and will continue to push forward the 3 pipeline assets for NXP002, NXP004 and NXP001, according to the strategy, as she has done so far since joining. All these projects are proceeding according to plan towards the inflection points previously communicated and all activities will continue to be progressed. The licensing discussions with Oxilio for NXP001 are ongoing and further news on this will be announced via RNS as soon as it is available. I do not doubt Anne’s commitment during this time.
As previously disclosed, we are expecting important readouts on the progress with NXP002 and NXP004 later in 2021 and positive outcomes on these will trigger licensing discussions with key players. Should this be the case, we will engage expertise in business development to pick up these projects. Even without any short term licensing income, the Company is funded through to the first inflection point for NXP002, to complete the research on NXP004, license NXP001 and to fund licensing discussions for a sufficient runway after getting data. As a Board, we are committed to navigating the Company through the next six months and beyond to achieve the best outcomes for our investors.
I would like to take this opportunity to thank our shareholders for their unwavering support and I look forward to updating you further with news as soon as we can.
Yours sincerely,
Alastair Riddell Non-Executive Chairman
It looks like some 350,000 shares have been sold in chunks since the 16th July, I feel more confident now that we are close to the bottom so have averaged down this morning with a 7500 buy. It would be good to see the board doing the same, or maybe they just can not at this time. GLA Here to ABDX.
Looking at some of the early trades yesterday morning and I don't think I have ever seen so many small trades going through with other companies. Between open and lunch time (9th March) there was around 35+ small trades all under £30, no idea why. Whatever the reason it seems to have got the price spread to realistic levels. Here's to Proteomics. GLA.
Open Offer to Qualifying Shareholders
In order to provide Shareholders who have not taken part in the Placing or the Subscription with an opportunity to participate in the Fundraising, the Company intends to make an Open Offer to Qualifying Shareholders on the terms and conditions to be set out in the Circular. The Open Offer provides Qualifying Shareholders with the opportunity to subscribe at the Issue Price for an aggregate of up to 13,946,397 Open Offer Shares to raise up to approximately £4.2 million (before fees and expenses) for the Company, on the basis of:
2 Open Offer Shares for every 17 Ordinary Shares held as at the Record Date.
The Open Offer is conditional on the Placing and the Subscription becoming or being declared unconditional in all respects and not being terminated before Admission. Accordingly, if the conditions to the Placing and the Subscription (including the passing of the Fundraising Resolutions) are not satisfied or waived (where capable of waiver), the Open Offer will not proceed.
Further details of the Open Offer and the terms and conditions on which it is being made, including the procedure for application and payment, will be contained in the Circular, which shall be posted to Shareholders and made available on the Company's website, www.shieldtherapeutics.com, on or around 1 March 2021. A further announcement will confirm the posting date and availability of the Circular on the Company's website.
Capitalised terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the announcement of the Transaction made via RNS on 26 February 2021.
Yes the spread is a put off, but there does seem to be some momentum gathering. If you time it right you can sneak one a 5% spread out of them !!
Looking at the late trades I am hoping for another solid start to day with an open of 105p (without RNS)
I certainly feel more relaxed this week, the future looks bright. GLA
Manchester, UK - 22 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partnership with Newcastle Premier Health Limited1 ("NPH"), a leading provider of independent medical services in Newcastle and the North East, will supply COVID-19 PCR testing services to Leeds Bradford Airport from the Company's laboratory in Manchester.
Yourgene and NPH are partnering with Leeds Bradford Airport2 ("LBA") to offer an onsite COVID-19 service for departing and arriving passengers, and for the local community. NPH has successfully implemented a similar testing service at Newcastle Airport and will now look to mirror that offering at LBA , using Yourgene's Clarigene® SARS-CoV-2 assay and its high throughput COVID-19 service laboratory in Manchester to test samples taken at the airport.
Together NPH and Yourgene will be offering 'Test To Release' for arriving international travellers, 'Fit to Fly' test certificates for departing passengers, and also general PCR coronavirus testing for the general public that live in the surrounding region. This testing service becomes available today at the airport in anticipation of a relaxation of lockdown rules in the near future. NPH is the sole provider of COVID-19 testing to LBA and Yourgene is the sole COVID-19 testing provider to NPH for the LBA contract.
Yourgene Genomic Services is a UK Government approved COVID-19 private testing provider for the Test to Release for International Travel scheme and for general coronavirus testing, as announced by the Company on 24 December 2020.
Lyn Rees, CEO of Yourgene commented: "We are thrilled to be partnering with NPH and Leeds Bradford Airport to offer our accurate, reliable and trusted COVID-19 testing service. While the timing of any lockdown relaxations and increases in passenger traffic are unclear at present, we are primed for when these restrictions are lifted at Leeds Bradford and other travel hubs around the country.
"We are proud to be part of the global effort to fight this pandemic by offering a high-class Genomics Services laboratories to our partners."
As Pahoo pointed out 'Seller in the background has finished'19-Feb-21 Taking a closer look
19-Feb-21 14:29:37 93.425 200,000 Sell* 95.00 100.00 186.85k O
19-Feb-21 14:29:52 91.75 100,000 Sell* 95.00 100.00 91.75k O
Both listed as sells, but at 14:29:37 the prices were 93.425, suggesting the 14:29:52 was a natural sell, then we had two larger buys before the bell at 16:30hrs, helping to push us up.
After the frenzy this weekend ..(ODX and others) I suspect that Monday morning will be a solid blue start. If so, nice one PAH00 : )
Today, I took an Innova test at a local pharmacy, (very helpful and professional) I received my notification via text 35 minutes later (test result negative) but there was no mention that the Innova test may only have a sensitivity of 78.3%. ! If this testing is going to work, we need 95%+ sensitivity, and it needs to be turned around in super quick time in a manner that stands scrutiny to the venues or work places that we are going to be returning to. This is where ABDX will shine.!